ScoreWhy is Xiangxue Pharmaceutical Co., Ltd. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -12.88% and Operating profit at -222.69% over the last 5 years
- The company has a negative book value of Rs 471.47 crore
2
The company has declared Negative results for the last 8 consecutive quarters
- NET PROFIT(HY) At CNY -1,140.39 MM has Grown at -56.15%
- INTEREST(HY) At CNY 151.22 MM has Grown at 38.14%
- ROCE(HY) Lowest at -571.32%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 12.85%, its profits have fallen by -51.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Xiangxue Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xiangxue Pharmaceutical Co., Ltd.
-49.73%
3.62
51.56%
China Shanghai Composite
0.9%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-12.88%
EBIT Growth (5y)
-222.69%
EBIT to Interest (avg)
-1.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.24
Sales to Capital Employed (avg)
0.57
Tax Ratio
3.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.51%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-13.84
EV to EBIT
-12.20
EV to EBITDA
-15.68
EV to Capital Employed
9.81
EV to Sales
5.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-80.40%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 121.61 MM
NET PROFIT(HY)
Higher at CNY -268.15 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by -10.21% (YoY
OPERATING PROFIT(Q)
Highest at CNY 33.71 MM
OPERATING PROFIT MARGIN(Q)
Highest at 9.67 %
PRE-TAX PROFIT(Q)
Highest at CNY 0 MM
-25What is not working for the Company
NET PROFIT(9M)
At CNY -1,297.01 MM has Grown at -48.1%
INTEREST(9M)
At CNY 214.8 MM has Grown at 13.57%
ROCE(HY)
Lowest at -1,483.28%
RAW MATERIAL COST(Y)
Grown by 104.82% (YoY
CASH AND EQV(HY)
Lowest at CNY 144.74 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 0 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 0 times
NET SALES(Q)
At CNY 348.62 MM has Fallen at -8.77%
Here's what is working for Xiangxue Pharmaceutical Co., Ltd.
Net Profit
Higher at CNY -268.15 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 121.61 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Operating Profit
Highest at CNY 33.71 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 9.67 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 0 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY 0 MM has Grown at 100%
over average net sales of the previous four periods of CNY -336.1 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Raw Material Cost
Fallen by -10.21% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
At CNY 54.92 MM has Grown at inf%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (CNY MM)
Here's what is not working for Xiangxue Pharmaceutical Co., Ltd.
Interest
At CNY 214.8 MM has Grown at 13.57%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Net Sales
At CNY 348.62 MM has Fallen at -8.77%
over average net sales of the previous four periods of CNY 382.14 MMMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Cash and Eqv
Lowest at CNY 144.74 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 104.82% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
